The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

Journal of Hematology & Oncology

Review

Yong-Ping Song¹  Jian-min Wang²  He Huang³  Dai-hong Liu⁴  Er-lie Jiang⁵  Ming-Zhe Han⁵  Qi-Fa Liu⁶  Dao-bin Zhou⁷  Han-yun Ren⁸  Xiao-hui Zhang⁹  Lan-ping Xu⁹  Xiao-jun Huang^1,10  Jing Chen^1,11  Yong-rong Lai^1,12  De-pei Wu^1,13  Xiao-wen Tang^1,13  Zi-min Sun^1,14  Ming Jiang^1,15  Ting Liu^1,16  Xi Zhang^1,17 

[1] Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China;Changhai Hospital of Shanghai, Naval Medical University, Shanghai, China;First Affiliated Hospital of Zhejiang University, Hangzhou, China;General Hospital of PLA (People’s Liberation Army of China), Beijing, China;Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Hematologic Disease, Tianjin, China;Nanfang Hospital of Southern Medical University, Guangzhou, China;Peking Union Medical College Hospital, Beijing, China;Peking University First Hospital, Beijing, China;Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China;Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China;Peking-Tsinghua Center for Life Sciences, Beijing, China;Shanghai Children’s Medical Center, Shanghai, China;The First Affiliated Hospital of Guangxi Medical University, Guilin, China;The First Affiliated Hospital of Soochow Hospital, National Clinical Research Center for Hematologic Disease, Suzhou, China;The First Affiliated Hospital of University of Science and Technology of China, Hefei, China;The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China;West China Hospital, Sichuan University, Chengdu, China;Xinqiao Hospital, Army Military Medical University, Chongqing, China;

关键词: Consensus;    Allogeneic hematopoietic transplantation;    China;    Indication;    Conditioning regimen;    Donor selection;   

DOI  :  10.1186/s13045-021-01159-2

 received in 2021-07-19, accepted in 2021-08-30,  发布年份 2021

来源: Springer

【 摘 要 】

The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HSCT in China and progressive integration with the world. There have been new developments since the initial publication. To integrate recent developments and further improve the consensus, a panel of experts from the CSH recently updated the consensus recommendations, which are summarized as follows: (1) there is a new algorithm for selecting appropriate donors for allo-HSCT candidates. Haploidentical donors (HIDs) are the preferred donor choice over matched sibling donors (MSDs) for patients with high-risk leukemia or elderly patients with young offspring donors in experienced centers. This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.

【 授权许可】

CC BY   
© The Author(s) 2021

【 图 表 】

Fig. 1